Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J F Rossi

Showing results (101-110 of 120) with videos related to

Pageof 12
Sort By:
Cancer Research|March 1, 1988
Phenotypic and functional analysis of 1,25-dihydroxyvitamin D3 receptor mediated modulation of the human myeloma cell line RPMI 8226J F Rossi, B G Durie, C Duperray, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignanciesM H Gaspard, D Maraninchi, A M Stoppa, et al.
Bone Marrow Transplantation|January 1, 1990
Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remissionD Blaise, M H Gaspard, A M Stoppa, et al.
Blood|November 15, 1996
Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loopZ J Gu, V Costes, Z Y Lu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Pilot study of neoadjuvant ifosfamide, cisplatin, and etoposide in locally advanced non-small cell lung cancerJ L Pujol, J F Rossi, T Le Chevalier, et al.
Blood|May 1, 1995
Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cellsZ Y Lu, X G Zhang, C Rodriguez, et al.
International Journal of Cancer|February 18, 1998
Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancerM Ychou, A Pelegrin, P Faurous, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'ImmunothérapeB Escudier, C Chevreau, C Lasset, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 1998
Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 TrialP Solal-Céligny, E Lepage, N Brousse, et al.
The New England Journal of Medicine|July 11, 1996
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du MyélomeM Attal, J L Harousseau, A M Stoppa, et al.
Pageof 12

Showing results (101-110 of 120) with videos related to

Sort By:
Pageof 12
Cancer Research|March 1, 1988
Phenotypic and functional analysis of 1,25-dihydroxyvitamin D3 receptor mediated modulation of the human myeloma cell line RPMI 8226J F Rossi, B G Durie, C Duperray, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignanciesM H Gaspard, D Maraninchi, A M Stoppa, et al.
Bone Marrow Transplantation|January 1, 1990
Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remissionD Blaise, M H Gaspard, A M Stoppa, et al.
Blood|November 15, 1996
Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loopZ J Gu, V Costes, Z Y Lu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Pilot study of neoadjuvant ifosfamide, cisplatin, and etoposide in locally advanced non-small cell lung cancerJ L Pujol, J F Rossi, T Le Chevalier, et al.
Blood|May 1, 1995
Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cellsZ Y Lu, X G Zhang, C Rodriguez, et al.
International Journal of Cancer|February 18, 1998
Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancerM Ychou, A Pelegrin, P Faurous, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'ImmunothérapeB Escudier, C Chevreau, C Lasset, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 1998
Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 TrialP Solal-Céligny, E Lepage, N Brousse, et al.
The New England Journal of Medicine|July 11, 1996
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du MyélomeM Attal, J L Harousseau, A M Stoppa, et al.
Pageof 12